Stable Packaging Cell Line (PCL) Platform

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs' PCL platform takes viral vector manufacturing to the next level!

Viral vectors are useful experimental tools for stable gene delivery and have been used to treat cancer in immunotherapy (such as chimeric antigen receptor T cell therapy, CAR-T). Lentiviral vectors are usually produced using a transient process of transfecting plasmid DNA into production cells. However, this method is expensive, has poor reproducibility, and is difficult to scale up. Manufacturing large amounts of materials for later clinical trials and product commercialization is still a challenge using this process.

The production of stable cell lines facilitates a GMP-compliant process, providing easier scale-up, reproducibility, and cost-effectiveness. At Creative Biolabs, we have developed a highly efficient Stable Packaging Cell Line (PCL) Platform specifically designed for the CAR virus vector scalable production. Through a proprietary packaging and producer cell lines optimization strategy, our PCL platform enables high-performance virus vector production from preclinical research-grade and smaller amounts up to large scale production in significantly reduced timelines. In addition, our PCL platform enables consistent quality virus delivery, cost-effective manufacturing, and minimize process risks. No need for helper viruses, expensive transfection reagents, or cGMP-grade plasmids. Just propagate our packaging cell lines and switch on production.

Premium Technology Platform For Premium Therapies

Viral vectors have been widely used for gene transfer, and each virus has its unique functions, making it suitable for specific treatments. We have used inducible and constitutive systems to generate multi-suspension and adhesion-based stable lentiviral vector packaging cell lines. In addition to lentiviral vectors, we also provide effective host cell lines for the production of AAV and adenoviral vectors. These cell lines can be used not only for the large-scale production of CAR viruses, but also for the production of viral vaccines, oncolytic viruses, and exosomes.

Fig.1 Proposed steps for lentiviral vector production in a packaging cell line.

Advantages of Our PCL Platform

High Stablity: All components produced by AAV are stably integrated into one producer cell line
High performance: Generate high-titer clones
Scalable: Scale up from shake flasks to large bioreactors without reducing productivity
Consistent quality: eliminate the variability of the transient transfection process
Fast: Automation greatly improves throughput and can identify the best clone
Economical: save the cost of plasmid and transfection reagent
Ready to use: GMP-compliant cell line

If you are interested in our services, please send an email to contact us, and our team will get back to you as soon as possible.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION